FDA approves third over-the-counter opioid overdose nasal spray

The FDA has greenlit a third over-the-counter naloxone nasal spray, Rextovy, to combat opioid overdoses, making it easier and more affordable for people to access this life-saving drug. Naloxone rapidly reverses the effects of opioids, and now being available without a prescription could significantly increase its availability, potentially saving countless lives. This move reflects a growing recognition of the opioid crisis and aims to empower more individuals to act swiftly in overdose emergencies, underscoring the importance of accessible medical interventions.